Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
151-165 of 4385 results
Synthorx raises $10m to develop and scale novel protein therapeutics
Synthorx has completed a $10m Series B financing, led by RA Capital Management and joined by Series A investors Avalon Ventures and Correlation Ventures.
Drug Research > Drug Discovery & Development > News
VBI Vaccines applies eVLP Platform to develop novel vaccine candidate to prevent Zika virus
VBI Vaccines has applied its clinical-stage eVLP Platform to the development of a novel vaccine candidate to prevent Zika virus infection.
Drug Research > Drug Discovery & Development > News
Vernalis achieves milestone in oncology drug discovery collaboration with Servier
Vernalis and Servier announced the achievement of a new milestone in their first oncology drug discovery collaboration, triggering a payment of €500K to Vernalis.
Drug Research > Drug Discovery & Development > News
Poxel closes €26.5m capital increase
POXEL, a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, announced the closing of a capital increase of 3,400,000 new ordinary shares without preferential subscription rights reserved for a category of investors for a total amount of €26.5m.
Drug Research > Drug Discovery & Development > News
Ardelyx agrees to raise $110m in private placement
By PBR Staff Writer
Clinical-stage biopharmaceutical firm Ardelyx has agreed to raise $110m in a private placement.
Drug Research > Drug Discovery & Development > News
Panther Biotechnology starts formal development of Transferrin Doxorubicin conjugate
Panther Biotechnology has initiated the formal drug development process for its lead compound, Transferrin Doxorubicin (TRF-DOX).
Drug Research > Drug Discovery & Development > News
ProMIS starts new program to find novel Alzheimer’s disease targets on toxic strains of protein tau
ProMIS Neurosciences has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Aβ), are implicated in the development of Alzheimer’s disease (AD).
Drug Research > Drug Discovery & Development > News
Avacta, Glythera collaborate to develop alternatives to antibody drug conjugates
By PBR Staff Writer
Avacta Group and Glythera have partnered to develop a new, highly targeted bio-therapeutics as an alternative to established antibody drug conjugates.
Drug Research > Drug Discovery & Development > News
Abzena and US research institute form immunotherapy joint venture
By PBR Staff Writer
UK life sciences firm Abzena has joined hands with the Texas-based Baylor Scott & White Research Institute (BSWRI) to develop novel immunotherapies for cancer and other diseases.
Drug Research > Drug Discovery & Development > News
Roivant Sciences, Plexcera Therapeutics establish new biopharmaceutical firm Enzyvant Sciences
Roivant Sciences and Plexcera Therapeutics have announced the formation of Enzyvant Sciences, a new biopharmaceutical company focused on the development of recombinant human acid ceramidase (rhAC), an enzyme replacement therapy for the treatment of patients with Farber disease.
Drug Research > Drug Discovery & Development > News
Seres Therapeutics, Emulate collaborate to support development of novel microbiome therapeutics
Seres Therapeutics, a microbiome therapeutics platform company, and Emulate, a private firm commercializing the Organs-on-Chips technology, announced a new collaboration.
Drug Research > Drug Discovery & Development > News
Sapience Therapeutics raises $22.5m in Series A financing
Sapience Therapeutics, a biotechnology company focused on developing novel therapeutics to address difficult to treat oncology indications, has raised $22.5m in a Series A financing.
Drug Research > Drug Discovery & Development > News
X-Chem, Bayer expand drug discovery collaboration
By PBR Staff Writer
X-Chem and Bayer have expanded a global drug discovery collaboration launched in 2012 across several therapeutic areas and target classes.
Drug Research > Drug Discovery & Development > News
Evotec, ANTRUK collaborate to discover antibiotic resistance breakers
By PBR Staff Writer
Evotec and Antibiotic Research UK (ANTRUK) have partnered to discover antibiotic resistance breakers (ARBs).
Drug Research > Drug Discovery & Development > News
Sprint Bioscience collaborates with US drug development firm on tumor metabolism program
Sprint Bioscience and a US drug development company have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism.
Drug Research > Drug Discovery & Development > News
151-165 of 4385 results